Pfizer and French partner to seek approval for Lyme disease vaccine after late-stage trial
The Big Market Report Take
Pharmaceutical giant Pfizer and French partner Valneva on Monday said they planned to seek regulatory approval for a Lyme disease vaccine after a late-stage trial.
Not financial advice. The Big Market Report aggregates news for informational purposes only. Nothing on this site constitutes investment advice. Equities and other securities are subject to market risk. Always do your own research and consult a qualified financial advisor before making any investment decisions. Full disclaimer →
Never miss a story
More from this section
- Coffee Empire Neumann Confronts New Era of Turbulent PricesBloomberg Markets12m ago
- Goldman Sachs: Selloff Represents Good Entry Point For InvestorsSeeking Alpha14m ago
- Ten Ways Americans Can Cut Oil UseYahoo Finance17m ago
- India’s Regulator Eases Rules for Foreign Funds to Settle TradesBloomberg Markets19m ago
- VNET Group: Good Opportunity To BuySeeking Alpha19m ago